Detailed Mechanism Funding and Narrative

Years of mechanism: 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 13340
Country/Region: Kenya
Year: 2016
Main Partner: FHI 360
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $11,863,623 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,831,612
Care: Orphans and Vulnerable Children (HKID) $1,308,721
Care: TB/HIV (HVTB) $603,754
Care: Pediatric Care and Support (PDCS) $332,338
Strategic Information (HVSI) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $382,359
Testing: HIV Testing and Counseling (HVCT) $1,560,771
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,787,386
Treatment: Adult Treatment (HTXS) $3,703,927
Treatment: Pediatric Treatment (PDTX) $352,755
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 2017 1,330
GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 2017 1,330
GEND_GBV_DSD Number of people receiving post-GBV care 2017 1,330
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 25,307
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 26,329
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 407,238
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 219,281
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 678,155
HTC_TST_DSD Service Delivery Point (Facility): Index testing 2017 2,429
HTC_TST_DSD Service Delivery Point (Facility): Inpatient 2017 49,664
HTC_TST_DSD Service Delivery Point (Facility): Other PITC 2017 48,833
HTC_TST_DSD Service Delivery Point (Facility): Outpatient 2017 296,423
HTC_TST_DSD Service Delivery Point (Facility): Pediatric 2017 51,928
HTC_TST_DSD Service Delivery Point (Facility): PMTCT 2017 141,415
HTC_TST_DSD Service Delivery Point (Facility): VCT 2017 79,809
HTC_TST_DSD Service Delivery Point (Facility): VMMC 2017 7,591
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2017 51,636
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2017 626,519
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2017 678,155
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Female 2017 933
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Male 2017 1,074
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 10,535
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 5,430
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 1,050
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 1,102
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 11,542
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 6,216
HTC_TST_TA Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 19,910
HTC_TST_TA Service Delivery Point (Facility): Index testing 2017 86
HTC_TST_TA Service Delivery Point (Facility): Inpatient 2017 301
HTC_TST_TA Service Delivery Point (Facility): Other PITC 2017 1,702
HTC_TST_TA Service Delivery Point (Facility): Outpatient 2017 12,289
HTC_TST_TA Service Delivery Point (Facility): Pediatric 2017 1,860
HTC_TST_TA Service Delivery Point (Facility): PMTCT 2017 865
HTC_TST_TA Service Delivery Point (Facility): VCT 2017 2,806
HTC_TST_TA Sum of Aggregated Age/Sex <15 2017 2,152
HTC_TST_TA Sum of Aggregated Age/Sex 15+ 2017 17,758
HTC_TST_TA Sum of Aggregated Age/Sex disaggregates 2017 19,910
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive <15 Female 2017 36
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive <15 Male 2017 64
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 380
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 194
OVC_SERV_DSD Age/Sex: 18+ Female 2017 4,237
OVC_SERV_DSD Age/Sex: 18+ Male 2017 4,747
OVC_SERV_DSD By Aggregated Age/Sex: <18 Female 2017 25,117
OVC_SERV_DSD By Aggregated Age/Sex: <18 Male 2017 25,386
OVC_SERV_DSD Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 59,487
OVC_SERV_DSD Sum of Age/Sex disaggregates 2017 8,984
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2017 2,187
PMTCT_ART_DSD New on ART 2017 2,272
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 144,094
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2017 2,762
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2017 1,178
PMTCT_EID_DSD Number of infants with a positive virological test result within 12 months of birth 2017 110
PMTCT_EID_DSD Number of infants with a positive virological test result within 2 months of birth 2017 54
PMTCT_EID_DSD Sum of Infant Age disaggregates 2017 3,940
PMTCT_STAT_DSD By: Known positives at entry 2017 2,165
PMTCT_STAT_DSD By: Number of new positives identified 2017 2,377
PMTCT_STAT_DSD Number of new ANC and L&D clients 2017 148,771
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 144,094
PMTCT_STAT_DSD Sum of Positives Status disaggregates 2017 4,542
TB_ART_DSD Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 37
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 667
TB_ART_DSD Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 35
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 611
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,485
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,350
TB_SCREENDX_DSD [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 2,775
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 2,775
TB_SCREENDX_DSD Screen Result: Screened Positive for TB 2017 2,775
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Female 2017 33,415
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Male 2017 15,721
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Female 2017 4,135
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Male 2017 1,948
TB_SCREENDX_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 55,219
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 134
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,365
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 227
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,339
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 4,065
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2017 4,484
TX_CURR_DSD Age/Sex: <1 2017 1
TX_CURR_DSD Aggregated Age/Sex: <15 Female 2017 2,602
TX_CURR_DSD Aggregated Age/Sex: <15 Male 2017 2,708
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2017 34,436
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2017 15,473
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2017 55,219
TX_CURR_DSD Sum of Aggregated Age/Sex <15 2017 5,310
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2017 49,909
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2017 55,219
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Female 2017 1,176
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Male 2017 963
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2017 11,808
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2017 5,307
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 19,254
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2017 19,254
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Female 2017 2,602
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Male 2017 2,708
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Female 2017 34,436
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Male 2017 15,473
TX_PVLS_DSD Denominator: Indication: Routine 2017 53,834
TX_PVLS_DSD Denominator: Indication: Targeted 2017 1,385
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 55,219
TX_PVLS_DSD Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 49,698
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Female 2017 2,343
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Male 2017 2,438
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Female 2017 30,989
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Male 2017 13,928
TX_PVLS_DSD Numerator: Indication: Routine 2017 48,452
TX_PVLS_DSD Numerator: Indication: Targeted 2017 1,246
TX_RET_DSD Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 8
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,176
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,023
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 963
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 836
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 11,808
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 10,254
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5,307
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,621
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 16,734
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 19,254
VMMC_CIRC_DSD By Age: 10-14 2017 3,296
VMMC_CIRC_DSD By Age: 15-19 2017 3,064
VMMC_CIRC_DSD By Age: 2 months - 9 years 2017 7
VMMC_CIRC_DSD By Age: 20-24 2017 571
VMMC_CIRC_DSD By Age: 25-29 2017 448
VMMC_CIRC_DSD By Age: 30-49 2017 185
VMMC_CIRC_DSD By Age: 50+ 2017 20
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2017 7,591
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 7,591
VMMC_CIRC_DSD Sum of age disaggregates (FY15-Current) 2017 7,584
VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 2017 6,951
Cross Cutting Budget Categories and Known Amounts Total: $100,000
Gender: Gender Based Violence (GBV) $100,000
GBV Prevention